Search ↗

Comparison

Semaglutide vs Survodutide

Both are GLP-1 & incretins, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, Semaglutide is the better documented of the two (regulator approved). That is a statement about the state of the literature, not a recommendation.

Semaglutide Survodutide
Class GLP-1 & incretins GLP-1 & incretins
Evidence Regulator approved Clinical trials
Human trials ~90 ~6
Half-life ~7 days ~6-7 days
Reported range 250 mcg - 2.4 mg 800 mcg - 6 mg
Frequency Once weekly, titrated over 16+ weeks Once weekly (trial protocols)
Routes Subcutaneous, Oral Subcutaneous
FDA approved Yes No
Research use only No Yes
Banned in sport No No
Studied for Type 2 diabetes, Chronic weight management, Cardiovascular risk reduction Investigational MASH treatment, Obesity research
Reported side effects Nausea, Vomiting, Diarrhoea, Constipation, Abdominal pain, Injection-site reactions Nausea, Vomiting, Diarrhoea, Increased heart rate

Semaglutide

Semaglutide is a GLP-1 analog with roughly 94% homology to native GLP-1, modified by substituting alpha-aminoisobutyric acid at position 8 to resist DPP-4 cleavage and by attaching a C18 fatty diacid chain that binds albumin. Together these give a half-life of about a week, allowing once-weekly dosing. It lowers blood glucose through glucose-dependent insulin secretion and glucagon suppression, slows gastric emptying, and acts on hypothalamic appetite centres to reduce energy intake. The STEP trial programme reported mean weight reductions near 15% of body weight at 68 weeks on 2.4 mg weekly.

Survodutide

Survodutide agonises both the glucagon receptor and the GLP-1 receptor, without the GIP activity of tirzepatide. The glucagon component increases energy expenditure and hepatic fat oxidation, which is why its most advanced programme is in metabolic dysfunction-associated steatohepatitis rather than obesity alone. Phase II data reported meaningful improvement in liver fibrosis endpoints alongside weight reduction.

Semaglutide vs Survodutide: common questions

What is the difference between Semaglutide and Survodutide?

Both are GLP-1 & incretins. Semaglutide: A long-acting GLP-1 receptor agonist and the compound that reset expectations for pharmacological weight loss. Survodutide: An investigational dual glucagon and GLP-1 receptor agonist, studied heavily in metabolic liver disease.

Which has stronger evidence, Semaglutide or Survodutide?

Semaglutide has the stronger evidence base (regulator approved, about 90 human studies) compared with Survodutide (clinical trials).

Are Semaglutide and Survodutide FDA approved?

Only Semaglutide is FDA approved (Type 2 diabetes mellitus (Ozempic, Rybelsus); Chronic weight management (Wegovy); Cardiovascular risk reduction in established CVD with overweight or obesity; Reducing the risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (Ozempic, January 2025); Noncirrhotic MASH with moderate to advanced liver fibrosis in adults (Wegovy, accelerated approval August 2025)). Survodutide is not approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 56843331) ↗ · structure, identifiers, synonyms
  2. DailyMed: FDA-approved labeling for Semaglutide ↗ · indications, dosing, warnings as approved
  3. FDA Drugs@FDA database ↗ · approval history
  4. CAS Registry Number 910463-68-2 ↗ · chemical identity
  5. PubChem compound record (CID 171378821) ↗ · structure, identifiers, synonyms
  6. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products

Published literature

  1. Wilding JPH, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.Diabetes Obes Metab 2022.PubMed 35441470 · doi:10.1111/dom.14725
  2. Rubino DM, Greenway FL, Khalid U, et al.. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA 2022.PubMed 35015037 · doi:10.1001/jama.2021.23619
  3. Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity.N Engl J Med 2021.PubMed 33567185 · doi:10.1056/NEJMoa2032183
  4. Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.JAMA 2021.PubMed 33755728 · doi:10.1001/jama.2021.3224
  5. Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.N Engl J Med 2025.PubMed 40353578 · doi:10.1056/NEJMoa2416394
  6. Wharton S, Freitas P, Hjelmesæth J, et al.. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.Lancet Diabetes Endocrinol 2025.PubMed 40961952 · doi:10.1016/S2213-8587(25)00226-8
  7. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.N Engl J Med 2023.PubMed 37952131 · doi:10.1056/NEJMoa2307563
  8. Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med 2021.PubMed 34170647 · doi:10.1056/NEJMoa2107519
  9. Sanyal AJ, Bedossa P, Fraessdorf M, et al.. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.N Engl J Med 2024.PubMed 38847460 · doi:10.1056/NEJMoa2401755
  10. Sinha B, Ghosal S. Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.Obesity (Silver Spring) 2025.PubMed 40685589 · doi:10.1002/oby.24360
  11. Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.Diabetes Care 2024.PubMed 38843460 · doi:10.2337/dci24-0003
  12. le Roux CW, Steen O, Lucas KJ, et al.. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.Lancet Diabetes Endocrinol 2024.PubMed 38330987 · doi:10.1016/S2213-8587(23)00356-X
  13. Newsome PN, Loomba R. Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.J Clin Invest 2025.PubMed 40590228 · doi:10.1172/JCI186425
  14. Kokkorakis M, Chakhtoura M, Rhayem C, et al.. Emerging pharmacotherapies for obesity: A systematic review.Pharmacol Rev 2025.PubMed 39952695 · doi:10.1124/pharmrev.123.001045
  15. Souza M, Al-Sharif L, Antunes VLJ, et al.. Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.Hepatology 2025.PubMed 39903735 · doi:10.1097/HEP.0000000000001254
  16. Singh A, Sohal A, Batta A. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.World J Gastroenterol 2024.PubMed 39735270 · doi:10.3748/wjg.v30.i48.5205

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.